Trillium Therapeutics PE Ratio 2013-2020 | TRIL

Current and historical p/e ratio for Trillium Therapeutics (TRIL) from 2013 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Trillium Therapeutics PE ratio as of August 04, 2020 is 0.00.
Trillium Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-08-04 7.25 0.00
2020-03-31 4.04 $-2.01 0.00
2019-12-31 1.03 $-1.40 0.00
2019-09-30 0.31 $-1.40 0.00
2019-06-30 0.33 $-1.76 0.00
2019-03-31 0.66 $-2.29 0.00
2018-12-31 1.71 $-2.34 0.00
2018-09-30 5.80 $-2.64 0.00
2018-06-30 6.00 $-2.78 0.00
2018-03-31 7.20 $-3.06 0.00
2017-12-31 7.25 $-3.65 0.00
2017-09-30 5.15 $-3.79 0.00
2017-06-30 4.40 $-3.73 0.00
2017-03-31 6.15 $-3.49 0.00
2016-12-31 5.65 $-3.65 0.00
2016-09-30 14.78 $-3.07 0.00
2016-06-30 8.98 $-2.45 0.00
2016-03-31 9.25 $-2.35 0.00
2015-12-31 12.61 $-1.88 0.00
2015-09-30 13.03 $-2.48 0.00
2015-06-30 21.82 $-2.32 0.00
2015-03-31 20.23 $-1.67 0.00
2014-12-31 9.00 $-0.88 0.00
2014-09-30 6.75 0 0.00
2014-06-30 9.90 0 0.00
2014-03-31 13.41 0 0.00
2013-12-31 11.67 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.613B $0.000B
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (`do not eat`) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (`eat`) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $73.920B 41.95
Takeda Pharmaceutical (TAK) Japan $57.916B 10.09
Astellas Pharma (ALPMY) Japan $29.770B 15.08
UCB SA (UCBJF) Belgium $24.702B 0.00
Eisai (ESALY) Japan $24.615B 20.80
Merck (MKGAF) Germany $17.008B 22.31
Catalent (CTLT) United States $13.659B 52.80
Grifols, S.A (GRFS) Spain $13.050B 15.95
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $11.669B 0.00
Neurocrine Biosciences (NBIX) United States $11.206B 43.38
Ono Pharmaceutical (OPHLF) Japan $9.254B 16.36
Ionis Pharmaceuticals (IONS) United States $8.253B 43.88
Orion OYJ (ORINY) Finland $7.077B 24.56
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.906B 0.00
STADA ARZNEIMI (STDAF) Germany $6.858B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.115B 10.14
United Therapeutics (UTHR) United States $5.067B 11.71
Arrowhead Pharmaceuticals (ARWR) United States $4.490B 490.22
Hypermarcas (HYPMY) Brazil $4.287B 15.77
Evotec AG (EVTCY) Germany $4.065B 109.55
Nektar Therapeutics (NKTR) United States $3.902B 0.00
FibroGen (FGEN) United States $3.729B 0.00
ChemoCentryx (CCXI) United States $3.359B 0.00
PTC Therapeutics (PTCT) United States $3.175B 0.00
Sage Therapeutics (SAGE) United States $2.585B 0.00
Cronos Group (CRON) Canada $2.477B 70.80
Taro Pharmaceutical Industries (TARO) Israel $2.457B 11.89
Pacira BioSciences (PCRX) United States $2.328B 47.65
Corcept Therapeutics (CORT) United States $1.798B 17.83
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.787B 0.00
Xencor (XNCR) United States $1.763B 0.00
Indivior (INVVY) United States $1.721B 21.36
USANA Health Sciences (USNA) United States $1.711B 16.12
Ironwood Pharmaceuticals (IRWD) United States $1.550B 11.86
Heron Therapeutics (HRTX) United States $1.532B 0.00
Akebia Therapeutics (AKBA) United States $1.425B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.395B 15.03
Revolution Medicines (RVMD) United States $1.388B 0.00
Zogenix (ZGNX) United States $1.340B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.276B 0.00
Karyopharm Therapeutics (KPTI) United States $1.152B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.102B 0.00
Esperion Therapeutics (ESPR) United States $1.091B 0.00
Tilray (TLRY) Canada $1.086B 0.00
VAXART, INC (VXRT) United States $0.970B 0.00
Translate Bio (TBIO) United States $0.968B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.954B 596.13
Altimmune (ALT) United States $0.902B 0.00
Endo (ENDP) Ireland $0.804B 1.25
BioCryst Pharmaceuticals (BCRX) United States $0.746B 0.00
Vectura Group (VEGPF) United Kingdom $0.737B 0.00
ImmunoGen (IMGN) United States $0.692B 0.00
Collegium Pharmaceutical (COLL) United States $0.572B 0.00
Radius Health (RDUS) United States $0.564B 0.00
Aerie Pharmaceuticals (AERI) United States $0.541B 0.00
Siga Technologies (SIGA) United States $0.535B 0.00
Flexion Therapeutics (FLXN) United States $0.517B 0.00
Molecular Templates (MTEM) United States $0.510B 0.00
TherapeuticsMD (TXMD) United States $0.505B 0.00
Ardelyx (ARDX) United States $0.505B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.497B 0.00
Innate Pharma SA (IPHYF) France $0.495B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.478B 18.63
Crinetics Pharmaceuticals (CRNX) United States $0.467B 0.00
DURECT (DRRX) United States $0.454B 0.00
Ocular Therapeutix (OCUL) United States $0.452B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.427B 10.32
Rigel Pharmaceuticals (RIGL) United States $0.415B 0.00
Organogenesis Holdings (ORGO) United States $0.400B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.395B 0.00
Calithera Biosciences (CALA) United States $0.352B 0.00
Harpoon Therapeutics (HARP) United States $0.327B 0.00
IMV INC (IMV) Canada $0.318B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.310B 0.00
PROFOUND MEDICL (PROF) Canada $0.296B 0.00
OptiNose (OPTN) United States $0.295B 0.00
MEI Pharma (MEIP) United States $0.290B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.284B 0.00
Concert Pharmaceuticals (CNCE) United States $0.269B 0.00
Redhill Biopharma (RDHL) Israel $0.261B 0.00
Lannett Co Inc (LCI) United States $0.250B 5.49
CASI Pharmaceuticals (CASI) United States $0.232B 0.00
Rafael Holdings (RFL) United States $0.221B 0.00
KalVista Pharmaceuticals (KALV) United States $0.198B 0.00
Taiwan Liposome (TLC) Taiwan $0.197B 0.00
Nivalis Therapeutics (ALPN) United States $0.193B 0.00
Nature's Sunshine Products (NATR) United States $0.190B 25.03
Onconova Therapeutics (ONTX) United States $0.186B 0.00
Aquestive Therapeutics (AQST) United States $0.184B 0.00
Heat Biologics (HTBX) United States $0.180B 0.00
Jounce Therapeutics (JNCE) United States $0.163B 3.90
Matinas Biopharma Holdings (MTNB) United States $0.161B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.139B 0.00
Xeris Pharmaceuticals (XERS) United States $0.120B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.117B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.116B 0.00
Champions Oncology (CSBR) United States $0.111B 0.00
Otonomy (OTIC) United States $0.110B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
CTI BioPharma (CTIC) United States $0.107B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.106B 0.00
Biomerica (BMRA) United States $0.106B 0.00
Recro Pharma (REPH) United States $0.103B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.103B 0.00
MediWound (MDWD) Israel $0.102B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.099B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.094B 0.00
Aclaris Therapeutics (ACRS) United States $0.092B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.091B 0.00
Hemispherx BioPharma (AIM) United States $0.091B 0.00
Lipocine (LPCN) United States $0.089B 0.00
ElectroCore (ECOR) United States $0.085B 0.00
CV Sciences (CVSI) United States $0.074B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.073B 0.00
SCYNEXIS (SCYX) United States $0.070B 0.00
Sundial Growers (SNDL) Canada $0.064B 0.00
PolarityTE (PTE) United States $0.062B 0.00
Infinity Pharmaceuticals (INFI) United States $0.059B 0.00
AgeX Therapeutics (AGE) United States $0.057B 0.00
Addex Therapeutics (ADXN) Switzerland $0.056B 0.00
RENEURON GP (RNUGF) United Kingdom $0.053B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.73
Novan (NOVN) United States $0.049B 0.00
IsoRay (ISR) United States $0.046B 0.00
GTx (ONCT) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.045B 0.00
Natural Alternatives (NAII) United States $0.044B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.043B 0.00
Mannatechorporated (MTEX) United States $0.043B 8.06
NovaBay Pharmaceuticals (NBY) United States $0.041B 0.00
Jaguar Animal Health (JAGX) United States $0.040B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.039B 83.73
Can-Fite Biopharma (CANF) Israel $0.038B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.036B 0.00
Neos Therapeutics (NEOS) United States $0.035B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.027B 0.00
India Globalization Capital (IGC) United States $0.027B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.019B 0.00
Iterum Therapeutics (ITRM) Ireland $0.019B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.019B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Flex Pharma (SLRX) United States $0.016B 0.00
Regulus Therapeutics (RGLS) United States $0.016B 0.00
RXi Pharmaceuticals (PHIO) United States $0.015B 0.00
Cyanotech (CYAN) United States $0.015B 34.71
China SXT Pharmaceuticals (SXTC) China $0.014B 0.00
Shineco (TYHT) China $0.013B 0.00
Midatech Pharma (MTP) United Kingdom $0.013B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.011B 0.00
Vical (BBI) United States $0.009B 0.00
HANCOCK JAFFE (HJLI) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.008B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00